Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Energy And Commerce Adds Pharma Provisions To Health Reform Bill

Executive Summary

The House Energy and Commerce Committee made a number of changes during markup of the America's Affordable Health Choices Act that will affect the pharmaceutical industry

You may also be interested in...



ASP Calculation Could Get Temporary Revision Under House Reform Bill

Drug wholesalers and physicians could get their wish of having the average sales price calculation for Medicare Part B drugs exclude customary prompt pay discounts, under a provision added to the House Energy and Commerce Committee's portion of health care reform legislation. But the fix, if kept in, would only last five years

ASP Calculation Could Get Temporary Revision Under House Reform Bill

Drug wholesalers and physicians could get their wish of having the average sales price calculation for Medicare Part B drugs exclude customary prompt pay discounts, under a provision added to the House Energy and Commerce Committee's portion of health care reform legislation. But the fix, if kept in, would only last five years

Part D Price Negotiation Provision In House Reform Bill Missing Its Teeth?

The House health care reform bill passed by the Energy and Commerce Committee directs HHS to negotiate drug prices directly with manufacturers for the Medicare Part D program, but it does not authorize HHS to establish a national formulary

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel